Sign inJoin waitlistJoin the waitlist

Eric Duncavage

Division Chief · Washington University/B-JH/SLCH Consortium

Credentials: · · · · · · · ·

History

Washington University/B-JH/SLCH Consortium
Present
Washington University/B-JH/SLCH Consortium
Present
Washington University/B-JH/SLCH Consortium
Present

Hematopathology
2011–2012
Clinical Informatics
2009–2011
Washington University/B-JH/SLCH Consortium
2008–2009
Pathology
Washington University/B-JH/SLCH Consortium
2004–2008
University of Tennessee College of Medicine
2000–2004

Research

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Blood · 2022 · 2,489 citations
Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American…
Journal of Molecular Diagnostics · 2017 · 1,704 citations
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
New England Journal of Medicine · 2016 · 716 citations

John Pfeifer
29 papers
David Spencer
24 papers
MW
Matthew Walter
24 papers
TL
Timothy Ley
23 papers
PW
Peter Westervelt
17 papers
JW
John Welch
16 papers · 1 as a fellow
Meagan Jacoby
16 papers
Daniel Link
15 papers
John DiPersio
15 papers
LW
Lukas Wartman
15 papers
Amanda Cashen
11 papers
Geoffrey Uy
10 papers

Grants

Whole Genome Sequencing for Genomic Evaluation and Risk Stratification of Patients with Myelodysplastic Syndromes
National Cancer Institute · UH3
Contact PI · $777.5K · Washington University
2022–2028
A Rapid and Comprehensive Approach for Clinical Genomic Profiling in Lung Cancer
National Cancer Institute · R33
Contact PI · $1.1M · Washington University
2023–2027
Genome Sequencing for Evaluating the Efficacy, Specificity, and Safety of Human Genome Editing
National Institute of Allergy and Infectious Diseases · U01
PI · $1.4M · Washington University
2023–2026
Whole Genome Sequencing for Genomic Evaluation and Risk Stratification of Patients with Myelodysplastic Syndromes
National Cancer Institute · UH2
Contact PI · $261.5K · Washington University
2022–2024

Clinical trials

Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
Sub-investigator · Recruiting
Washington University School of Medicine
2022–2027
Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant
Sub-investigator · Recruiting · Phase 1, Phase 2
Washington University School of Medicine
2022–2033
Aging, Geriatric Syndromes and Clonal Hematopoiesis
Sub-investigator · Recruiting
Washington University School of Medicine
2016–2030